Drug Profile
IGF-methotrexate conjugate - IGF Oncology
Alternative Names: 765-IGF-MTX; IGF-MTX; IGF/MTX; Insulin-like-growth-factor-methotrexate-conjugateLatest Information Update: 22 Jun 2022
Price :
$50
*
At a glance
- Originator IGF Oncology
- Developer IGF Oncology; University of Chicago
- Class Antineoplastics; Benzamides; Drug conjugates; Glutamates; Growth factors; Peptides; Pterins; Small molecules; Somatomedins
- Mechanism of Action Tetrahydrofolate dehydrogenase inhibitors; Thymidylate synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Myelodysplastic syndromes; Myeloid leukaemia
- No development reported Solid tumours
Most Recent Events
- 13 Jun 2022 IGF Oncology terminates a phase I/II trial in Myelodysplastic syndromes and Myeloid leukaemia (Late-stage disease, Second-line therapy or greater) in USA due to financial challenges of the sponsor (IV) (NCT03175978)
- 01 Jul 2020 IGF Oncology suspends a phase I/II trial in Myelodysplastic syndromes (Late-stage disease, Second-line therapy or greater) in USA due to financial challenges of the sponsor (IV) (NCT03175978)
- 28 Mar 2018 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in USA (IV, Infusion)